At a glance
ClinicalIndex Comparison RecordN/ACompleted· 100 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Pharmacogenetics on Pharmacokinetics and Toxicity of Doxorubicin in Egyptian Breast Cancer Patients
In Brief
An observational study for Breast Cancer. Completed, enrolled 100 participants across 1 site.
Detailed Summary
This study aims to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in doxorubicin transport and metabolism on its pharmacokinetics and toxicity in Egyptian breast cancer patients. It also aims to explore the association of pretreatment neutrophil to lymphocyte ratio (NLR) with pathological complete response (pCR).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesEgypt
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartOct 2021
Primary CompletionNov 2022
Study CompletionNov 2023
First PostedSep 2024
TodayJul 2026
First PostedSep 19, 2024
Enrollment StartOct 1, 2021
Primary CompletionNov 1, 2022
Study CompletionNov 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 1.8 years ago